Scientists hunt for hidden genes behind family blood cancer clusters
NCT ID NCT00039676
First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 7 times
Summary
This long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The goal is to better understand what causes these cancers and how to spot who is most at risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could identify genes and risk factors that lead to better screening and prevention strategies for blood cancers.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly help participants. Results may take years and might not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NIH National Cancer Institute - Shady Grove
Rockville, Maryland, 20850, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?